Cryopreservation by vitrification is the current state of the art in experimental organ preservation for transplant. Unlike methods in currently clinical use which only preserve large vascular organs in transplantable condition for hours, vitrification and storage below the glass transition temperature (~-130C) would enable safe storage for years or decades. Success with organ cryopreservation by vitrification would permit true banking of organs, increasing the number available, improving immune matching, and reducing wait list times.Two major limitations to this method are thermomechanical fracturing and the inherent biochemical toxicity of vitrification solutions. Arigos Biomedical is developing new technology that can both eliminate fracturing and reduce the effective toxicity of vitrifiable cryoprotectants. Preliminary experiments have demonstrated elimination of fractures in vitrified swine kidneys, as well as dramatically improved cooling rates from 0 to -100C, which reduce exposure time to cryoprotectant solutions.